<DOC>
	<DOCNO>NCT00567723</DOCNO>
	<brief_summary>Patients treat Fosrenol minimum 12 consecutive week receive dialysis follow 5 year compare mortality , bone fracture incidence select morbidity patient lanthanum exposure patient treat hyperphosphatemia market product .</brief_summary>
	<brief_title>Long Term Treatment End Stage Renal Disease Patients With Lanthanum Carbonate ( Fosrenol )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Test Group Signed inform consent Patient must ESRD receive dialysis Prior treatment Fosrenol minimum 12 consecutive week Primary payer healthcare must Medicare ( patient must supply Medicare Claim Number ) Patient must 18 year age old Test Group Patients meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>